|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.580 USD | -1.25% |
|
-10.73% | -36.55% |
| 05-20 | Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat | CI |
| 05-12 | Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 6.85M | - | - | - | - | - |
| 43.68B | |||||
| 30.65B | - | - | - | - | - |
| 30.4B | |||||
| 29.31B | |||||
| 24.2B |
Select your edition
All financial news and data tailored to specific country editions
